Lipocine (LPCN) Income from Continuing Operations (2012 - 2025)
Lipocine's (LPCN) quarterly Income from Continuing Operations came in at 3186832.0 in Q3 2025, down 43.63% YoY from 5653164.05 in Q3 2024, and down 44.48% on a QoQ basis from 2205716.0 in Q2 2025.
Lipocine (LPCN) Income from Continuing Operations (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Income from Continuing Operations data on file, last reported at 3186832.0 in Q3 2025.
- Quarterly Income from Continuing Operations fell 43.63% year-over-year to 3186832.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 5476454.0 (down 781.26% YoY) and the FY2024 annual result came in at 7136.0, up 100.06% from the prior year.
- Income from Continuing Operations declined to 3186832.0 in Q3 2025, from 2205716.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12757403.0 in Q4 2021 to a low of 6809041.0 in Q2 2021.
- A 5-year average of 1535127.32 and a median of 2631777.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations jumped 11857.32% — and 2023, when it sank 176.07%.
- Tracing LPCN's Income from Continuing Operations over 5 years: stood at 12757403.0 in 2021, then sank by 99.76% to 30040.0 in 2022, then jumped by 3736.2% to 1152395.0 in 2023, then surged by 54.54% to 1780967.0 in 2024, then plunged by 278.94% to 3186832.0 in 2025.
- The last three Income from Continuing Operations figures came in at 3186832.0 (Q3 2025), 2205716.0 (Q2 2025), and 1864873.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -2.21 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | -2.22 Mn |
| Jun 30, 2024 | -3.07 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | -6.65 Mn |
| Jun 30, 2023 | -3.55 Mn |
| Mar 31, 2023 | -3.87 Mn |
| Dec 31, 2022 | 30,040.00 |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -3.49 Mn |
| Dec 31, 2021 | 12.76 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Jun 30, 2021 | -6.81 Mn |
| Mar 31, 2021 | -3.37 Mn |
| Dec 31, 2020 | -108,506.00 |